Thoughts on the Market
2026-07-14 · Hosted by Mike Wilson · Morgan Stanley
Executive Summary
Morgan Stanley analysts Terence Flynn (US Pharma/Biotech) and Thibault Boutherin (Europe Pharmaceuticals) examined how the arrival of lower-cost semaglutide generics in India, Canada, and Brazil could preview what happens when GLP-1 patents expire in Europe (2031) and the US (2032). In India, where semaglutide's patent expired in March 2026, 13 companies launched 26 generics, driving a sixfold volume increase from February to April 2026 as affordability expanded the underpenetrated market; Morgan Stanley's India team projects the market will grow from $125 million in 2025 to more than $1 billion by 2030 despite lower prices. The analysts see no near-term bottleneck in API or device supply, but flagged fill-and-finish manufacturing capacity — which takes up to three years to build — as a potential constraint. Despite generic competition, they expect branded tirzepatide (which targets two pathways vs. semaglutide's one) to retain a premium segment via superior efficacy and tolerability, with US market share already at 60% in its favor. Oral GLP-1 formulations and expanded Medicare access (roughly 18 million additional patients at $50/month starting this summer) were cited as additional growth drivers.
Key Stories & Changes
1. Semaglutide Generics Launch in Three Markets
Generics introduced in 2026 across India, Canada, and Brazil
India: patent expired March 2026; 13 companies launched 26 generics across autoinjectors, vials, and pills, all priced below the branded drug
Canada: 2 generics launched so far, 4 more awaiting approval, additional filings pending
Brazil: 1 generic approved last month, launch expected in July; 17 other generics in various stages of regulatory review
Analysts frame these three markets as a "blueprint" for what could happen in the US and Europe, particularly Canada given its structural similarities to those markets
Patent expiration timeline: Europe 2031, US 2032
2. India Shows Sharp Volume Expansion From Lower Prices
Volume in April 2026 was six times higher than in February 2026
Generics captured 80% of semaglutide volume in India by April
Morgan Stanley's India team projects the GLP-1 market will grow from $125 million in 2025 to more than $1 billion by 2030, driven by volume rather than price
3. Supply Chain: No Near-Term Bottleneck, But Fill-and-Finish Is a Watch Item
Three supply chain elements: API (the semaglutide molecule), device/device components, and fill and finish
API: no bottleneck expected — large Chinese manufacturers are building multi-ton semaglutide capacity
Device: same suppliers serving branded and generic makers; meaningful investment underway, no bottleneck expected
Fill and finish: the most constrained link — requires highly controlled clean-room space, regulatory approval, and up to three years to build capacity; a bottleneck could emerge here absent further investment
4. Tirzepatide Positioned to Retain Premium Segment
Tirzepatide targets two pathways (GLP-1 and GIP) versus semaglutide's single pathway, delivering better efficacy and improved tolerability in comparative data (Type 2 diabetes and obesity)
Ex-US markets are already showing segmentation, with some consumers willing to pay a premium for tirzepatide even as cheaper generics enter
In the US, tirzepatide currently holds about 60% market share versus semaglutide
Morgan Stanley expects continued branded growth even amid generic entry, due to this segmentation dynamic
5. Oral GLP-1s and Medicare Access Expanding the Market
Oral GLP-1 formulations, initially for Type 2 diabetes, have broadened into obesity following recent FDA approvals; the majority of oral GLP-1 users in the US are new to GLP-1s, indicating genuine market expansion rather than cannibalization
Manufacturing complexity varies: non-peptide-based orals are easier to scale for a larger global market than peptide-based orals
Starting this summer, US Medicare patients (age 65+) will gain access to GLP-1s at $50/month, expanding access to an estimated 18 million additional people
Currently about 50% of US employers cover these medications, with coverage expected to rise as clinical data accumulates
6. Pipeline Innovation Beyond Current GLP-1s
Industry players are developing longer-acting formulations (monthly or less-frequent injections vs. today's once-weekly dosing)
New pathways beyond GLP-1/GIP under investigation include amylin and glucagon, with several late-stage pipeline candidates showing promising data
Goal of pipeline innovation: improve efficacy and/or tolerability versus existing medications, sustaining differentiation against generic competition
Trends Identified
1. Generic Entry Expands Rather Than Shrinks the Overall Market
The India experience — a sixfold volume increase alongside falling prices — suggests that in underpenetrated GLP-1 markets, affordability is the primary demand constraint, not efficacy or awareness. This implies that patent expirations in the US and Europe may ultimately grow the total addressable market even as branded pricing power erodes, a dynamic that changes how investors should think about "patent cliff" risk for GLP-1 makers.
2. Market Bifurcation Between Commodity Generics and Premium Branded Drugs
Across multiple international markets, the data shows segmentation forming between price-sensitive generic users and consumers willing to pay for superior branded efficacy (tirzepatide). This suggests the GLP-1 category may follow a two-tier structure similar to other pharmaceutical categories facing generic competition, where branded leaders retain pricing power in a premium segment even as overall market volume shifts toward lower-cost options.
3. Manufacturing Capacity, Not Chemistry, Is the Long-Term Constraint
With API and device supply expected to keep pace with demand, the analysts' focus on fill-and-finish capacity (requiring up to three years to build) signals that the binding constraint on how fast lower-cost GLP-1s can scale globally is industrial capacity investment, not patent or regulatory barriers. This is a structural, multi-year consideration for both generic and branded manufacturers positioning for the 2031-2032 patent cliffs in Europe and the US. ---
Sentiment Analysis
Overall Market Sentiment: Constructive
Both analysts framed the GLP-1 category's next phase — cheaper generics, oral formulations, and broader access — as expanding rather than threatening the overall market opportunity, while acknowledging genuine competitive and manufacturing risks.
Risk Factors Highlighted
Fill-and-finish capacity bottleneck: This manufacturing step requires up to three years to build out; insufficient investment could constrain generic supply growth.
Branded semaglutide erosion: Generic semaglutide entry directly challenges the existing branded version of the drug, particularly in newly opened international markets.
Oral drug manufacturing complexity: Peptide-based oral GLP-1s are harder to scale than non-peptide versions, creating potential capacity disparities across competing oral products.
Patent cliff timing uncertainty: While India/Canada/Brazil offer a preview, actual market dynamics in the US (2032) and Europe (2031) when patents expire may differ given different healthcare and reimbursement structures.
This episode was covered in today's [The Market Signal — 2026-07-14](https://marketsignal.beehiiv.com/p/the-market-signal-2026-07-14), a cross-source synthesis of multiple podcast reports.